Engflag

Ibusi

Quick links to important sections

Ibusi

Ibusi_EN

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Cardiac Therapy, Decongestant, Local Anesthetic, Nonsteroidal Anti-Inflammatory, Pain Reliever, Topical Products For Joint And Muscular Pain

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Period Pain, Backache, Pain, Sore Throat, Pain, Back, Bursitis, Headache, Influenza

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibusi

Property Description
Active Ingredient Ibuprofen
Form Oral (tablets, capsules, suspension) and Topical (gels, sprays)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Pain relief, inflammation, and fever reduction
Origin Synthetic (Propionic acid derivative)

What Type of Medicine is Ibusi and Its Classification?

Ibusi is a brand-name medicinal product whose active ingredient is Ibuprofen, which belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) pharmacological class. This classification identifies the drug as a synthetic, single-component agent primarily used to modulate the body's response to pain, inflammation, and fever.

The defining characteristic of Ibusi is its membership in the NSAID group, specifically as a propionic acid derivative. This places it among a category of medications clinically recognized for its reliable inhibitory effect on Cyclooxygenase (COX) enzymes. This triple-action profile is a distinctive feature of the drug, making it a comprehensive choice for managing mild to moderate discomfort, such as a common tension headache. Ibuprofen is an essential medicine recognized globally.

Composition, Origin, and Available Forms of Ibusi

The composition of Ibusi is based on a single active therapeutic agent: Ibuprofen, a substance first patented in 1961. This active ingredient is a synthetic compound, chemically manufactured to ensure consistent purity and predictable action.

Ibusi is formulated for both systemic and localized use, offering various dosage forms to patients. For internal use, it is commonly available in oral forms, such as film-coated tablets, capsules, or liquid suspensions often flavored for various patient groups. For external application, it is also available in topical forms, including gels or sprays, which allow for dermal absorption and localized relief. As an Over-The-Counter (OTC) product, Ibusi is easily accessible for self-management of common acute symptoms.

General Purpose: What Does Ibusi Help Relieve?

The general purpose of Ibusi is to deliver triple-action symptomatic relief by addressing pain, inflammation, and fever. The medication's core benefit is its ability to intervene in the body's inflammatory cascade. The mechanism of action for Ibuprofen involves the inhibition of prostaglandin synthesis, thereby producing its anti-inflammatory and analgesic effects. This inhibition is the core way the medicine helps ease discomfort by reducing the primary chemical triggers of pain and swelling.

This triple function makes Ibusi a fundamental tool for managing common discomforts. Its anti-inflammatory effect is crucial for reducing localized swelling and redness, while its analgesic effect alleviates the sensation of pain. Furthermore, the drug exerts an antipyretic effect, helping to lower an elevated body temperature. These general benefits define what the drug is fundamentally designed to achieve.

Regulatory References

  1. Ibuprofen on WHO EML
  2. Ibuprofen Mechanism of Action (NIH/NCBI)

What side effects are possible with Ibusi?

Possible Side Effects and Safety Information

The safety profile of Ibusi, as documented in official government regulatory information, is structured to highlight potential risks, particularly those deemed serious.

Serious Risks and Boxed Warnings

Official labeling contains a Boxed Warning regarding two major categories of serious, potentially fatal risks:

  • Cardiovascular Thrombotic Events: This includes an increased risk of heart attack (myocardial infarction) and stroke. The risk may increase with longer use and higher doses.
  • Gastrointestinal Adverse Events: This involves the potential for serious events such as bleeding, ulceration, and perforation (a hole) of the stomach or intestines, which can occur without warning symptoms.

Ibusi is contraindicated (should not be used) right before or after coronary artery bypass graft (CABG) surgery.

Adverse Reactions by Frequency

Side effects are categorized by government authorities based on how often they occur:

Classification Examples of Documented Reactions
Common Dyspepsia, abdominal pain, nausea, headache, dizziness.
Uncommon Rash, fluid retention and swelling, nervousness.
Rare Aseptic meningitis, visual disturbances, severe liver or kidney problems.

Serious adverse reactions also include severe allergic reactions (anaphylaxis) and severe skin reactions like Stevens-Johnson Syndrome (SJS).

Population and Exposure Limitations

The risk of serious adverse events is generally noted to be higher with higher doses and longer duration of use. The medicine is strongly contraindicated during the last trimester of pregnancy due to potential harm to the developing fetus.

Overdose and Emergency Response

Overdose and When to Seek Help: Ibuprofen Regulatory Profile

Overdose Scope: Recognized Clinical Manifestations

Overdose with this class of medication is classified as a serious risk. Documented presentations of overdose include a range of symptoms, primarily affecting the gastrointestinal tract and the central nervous system. Immediate signs may include nausea, vomiting, upper abdominal pain, lethargy, and drowsiness. Central nervous system effects can progress to include confusion, nystagmus (involuntary eye movement), coma, and convulsions (seizures).

Urgent Medical Attention Required

Due to the potential for severe or life-threatening complications, immediate medical help is required in all cases of suspected overdose. The most serious risks include acute renal failure, hepatic dysfunction, hypotension, and respiratory depression. Certain populations, such as children, may be at higher risk for central nervous system toxicity. In case of overdose, it is essential to seek emergency medical attention immediately or contact a certified Poison Control Center right away. Do not attempt to treat the situation yourself or delay seeking professional help. The recommended course of action for overdose includes supportive care and, in certain circumstances, measures to reduce drug absorption.

Therapeutic Uses of Ibusi

Ibusi (Ibuprofen) is generally used for managing symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states. The medication is relevant across domains where short-term symptomatic assistance is needed, such as in situations involving acute pain, fever, and symptoms related to inflammatory or irritative states.

Therapeutic Scope

Ibusi is relevant for easing challenging symptomatic manifestations across key areas, including headache, toothache, menstrual cramps (primary dysmenorrhea), and discomfort from musculoskeletal injuries. It is also commonly used in conditions characterized by elevated body temperature where its antipyretic effect supports the effort to lower fever and is used for managing associated systemic symptoms like body aches during episodes of cold or flu. The medication contributes to improved comfort during periods of heightened symptoms. Conditions involving recurrent or episodic manifestations may use the medication as part of symptomatic management for conditions involving heightened symptoms, such as pain, stiffness, and localized redness associated with osteoarthritis and rheumatoid arthritis. This provides support that helps ease the overall symptom burden when symptoms interfere with routine activities.

Quick Fact: Relief for Swelling and Stiffness Ibusi is applied in clinical settings that involve inflammatory or irritative states to help reduce associated symptoms like swelling and stiffness, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ibusi (Ibuprofen)

This section outlines the eligibility and non-eligibility criteria for ibuprofen, strictly based on official governmental regulatory documents.

Absolute Contraindications (Must Not Use)

Population/Condition Restriction Basis
Allergy/Hypersensitivity Known allergic reactions (including asthma or urticaria) to ibuprofen, aspirin, or other NSAIDs (Nonsteroidal Anti-inflammatory Drugs).
Bleeding/GI Status Presence of active gastrointestinal bleeding or peptic ulceration (current or recurrent).
Cardiac Procedures For pain treatment immediately before or after Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy At or after 20 weeks gestation (risk of fetal renal dysfunction) and throughout the third trimester (risk of premature closure of the fetal ductus arteriosus).
Severe Organ Failure Severe hepatic (liver) or severe renal (kidney) failure.

Conditional Use and Restrictions

Population/Condition Condition/Limitation
Older Adults Typically geq 60 or geq 65 years: Use is restricted due to increased risk of heart failure, renal, and GI complications.
Organ Impairment Mild-to-moderate hepatic or renal impairment requires caution and possible dose limitation.
Cardiovascular Disease Use is restricted in patients with Congestive Heart Failure or existing cardiovascular risk factors.
Pediatric Use Generally restricted for use in infants under 6 months of age or mathbf< 20 kg (depending on formulation).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ibusi (Ibuprofen) has documented interaction patterns based on official regulatory labeling, primarily involving pharmacokinetic effects on clearance and pharmacodynamic additive effects.

Documented Interaction Classifications

Classification Interacting Agents / Classes Official Regulatory Outcome
Contraindicated Combinations Other NSAIDs (including COX-2 inhibitors) Increased risk of serious adverse events (e.g., gastrointestinal bleeding).
Peri-operative Pain in CABG Setting Restricted use as officially contraindicated for pain treatment in this context.
Pharmacokinetic Effects CYP2C9 Inhibitors (e.g., Fluconazole) Co-administration may increase plasma exposure of Ibuprofen.
Lithium, Methotrexate Ibusi officially reduces the clearance of these medicines, leading to increased plasma concentrations.
Pharmacodynamic Effects Anticoagulants, Antiplatelets, SSRIs/SNRIs Potentiates the risk of hemorrhage due to additive effects.
Diuretics, Antihypertensives Reduces the official natriuretic and blood pressure-lowering effect.

Interaction-Related Restrictions and Constraints

Co-administration with immediate-release low-dose Aspirin (typically leq 81 mg for antiplatelet effect) requires a specific timing separation as stated in regulatory labels: Ibusi must be taken at least 30 minutes after or at least 8 hours before the Aspirin dose to mitigate interference with its antiplatelet activity. Co-administration with alcohol is officially documented to increase the risk of serious gastrointestinal bleeding. Furthermore, regulatory sources note that elderly patients have a higher documented risk of serious adverse reactions from interactions, particularly those affecting the gastrointestinal tract and renal function.

Mechanism of Action

Inhibition of the Prostanoid Synthesis Pathway

Ibusi exerts its core molecular action as a reversible, non-selective inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). By competitively blocking the COX enzymes, the drug suppresses the synthesis of key downstream chemical mediators, primarily prostaglandins ( PGE2 and PGI2).

Alteration of Peripheral Nociceptive Signaling

The resulting reduction in prostaglandin concentrations at peripheral sites decreases the chemical sensitization of peripheral nerve endings (nociceptors). Prostaglandins typically amplify discomfort signals; therefore, the mechanism alters the transmission characteristics within the nociceptive signaling pathway, reducing the effect of high mediator concentrations on nerve fibers.

Disruption of Central Thermoregulatory Control

For its antipyretic effect, the drug's action extends to the central nervous system (CNS). Inhibition of PGE2 synthesis within the hypothalamus removes the signal that elevates the body's thermal set point. This physiological change results in heat dissipation as the core body temperature set point is lowered.

Dosage and Administration Information

How to Use Ibusi: Official Administration Guidelines

Ibusi (Ibuprofen) is administered according to specific procedural guidelines to ensure consistent and correct usage. The official administration scope covers multiple routes and mandates specific dosing based on whether the product is available over-the-counter (OTC) or by prescription (Rx).

Administration Scope

Entity Instruction
Route of administration Oral (tablets, suspension), Intravenous (IV) Infusion, and Topical.
Dosing schedule (Adults) Rx: 400 mg to 800 mg per dose; Maximum Daily Dose (MDD) is 3200 mg. OTC: 200 mg to 400 mg per dose; MDD is 1200 mg.
Frequency pattern Typically administered every 4 to 6 hours for acute symptoms, or in divided doses 3 to 4 times daily for chronic inflammatory conditions.
Timing in relation to meals Oral forms are generally recommended to be taken with food or milk to lessen gastric irritation.
Preparation requirements Oral suspension must be shaken well before measurement; IV solutions must be diluted prior to infusion to a concentration of 4 mg/ mL or less.
Age-group rules Dosing for children is determined by body weight (mg/kg). For older adults, the lowest effective dose for the shortest duration is mandated due to increased sensitivity.

Official Use Protocol

Administration adheres to the principle of using the lowest effective dose for the shortest duration necessary to control symptoms. The IV solution is administered as a slow intravenous infusion over 30 minutes in adults. If a dose is missed, the instruction is to skip the missed dose if it is close to the time for the next scheduled dose, and not to double the dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ibusi

Evidence for Use in Acute Pain and Fever Reduction

Research has extensively examined Ibusi for research exploring outcomes related to physical discomfort, specifically acute, mild-to-moderate pain, and for studies involving systemic imbalances such as fever. The research base includes numerous short-term Randomized Controlled Trials (RCTs), where the medicine was studied against inactive substances (placebo) or other commonly used pain relievers. Studies monitored outcomes related to acute changes, including changes in pain intensity measured using standardized scales. Data show patterns related to dose amounts, and findings describe patterns where increasing the dose beyond a certain point was associated with no further measured changes in pain scores. Follow-up durations were limited in most acute trials, and existing studies provide limited insight into the long-term patterns of using the medicine intermittently for recurring episodes.

Evidence for Use in Primary Dysmenorrhea and Chronic Conditions

Ibusi was studied for its use in conditions associated with acute or disruptive episodes, such as primary dysmenorrhea (menstrual cramps), and for chronic conditions characterized by fluctuating manifestations, such as osteoarthritis. For primary dysmenorrhea, short-term RCTs assessed outcomes related to physical discomfort and how pain intensity scores changed. For chronic uses, the evidence base includes intermediate-term RCTs and longer-term observational studies. These studies examined outcomes reflecting daily functioning or activity level, measured alongside patient-reported scores for stiffness and pain. Research also explored topical formulations for studies of localized conditions linked to inflammatory states.

What Research Gaps and Uncertainties Remain

The research landscape highlights what is known — and what is still uncertain — about the medicine. Limited information for long-term outcomes is a recognized gap, especially from controlled trials in the chronic-use setting. The research does not determine whether an individual will respond similarly to the group patterns observed in the studies, and comparative evidence is lacking for many specific, long-term regimens. Subgroup findings are uncertain in several areas, including research focusing on patients with certain existing comorbidities or specific disease subtypes.

Key Studies & References

  1. A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma
  2. Analgesic Efficacy of Ibuprofen in Dysmenorrhea (Comparative Trials/Review)
  3. WHO Model List of Essential Medicines (Core Indications and Status)
  4. Ibuprofen Pathway, Pharmacodynamics (Source for study mechanisms and outcomes)

How should Ibusi be stored and disposed of?

The storage and disposal of Ibusi (Ibuprofen) must follow official regulatory requirements to maintain product integrity and safety.

Ibusi requires storage at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and maintained tightly closed to protect it from excessive moisture. Liquid formulations should not be frozen. All forms of Ibusi must be stored out of the reach and sight of children.

For disposal, unused or expired medication should be handled properly, often through authorized take-back programs. Official guidelines advise not to flush the product down the toilet and instead recommend consulting a local pharmacist or waste disposal company for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Ibusi found in:

A-Z Index: